Conference Proceedings

Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia

Courtney D DiNardo, Daniel A Pollyea, Brian A Jonas, Marina Konopleva, Vinod Pullarkat, Andrew Wei, Hagop M Kantarjian, Arnaud Pigneux, Christian Recher, John F Seymour, Martin Dunbar, Tu Xu, Mack Mabry, Jalaja Potluri, Keith Pratz, Anthony Letai

BLOOD | AMER SOC HEMATOLOGY | Published : 2017

Grants

Funding Acknowledgements

DiNardo: Agios: Honoraria, Research Funding; Daiichi-Sankyo: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding. Pollyea: Takeda, Ariad, Alexion, Celgene, Pfizer, Pharmacyclics, Gilead, Jazz, Servier, Curis: Membership on an entity's Board of Directors or advisory committees; Agios, Pfizer: Research Funding. Jonas: AbbVie, Celgene, Daiichi Sankyo, Pharmacyclics, Genentech/Roche, Glycomimetics, Esanex, Kalobios: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees; Rigel: Consultancy. Wei: AbbVie, Celgene, Novartis, Amgen, Servier: Membership on an entity's Board of Directors or advisory committees; AbbVie, Celgene, Servier: Research Funding; AbbVie, Celgene, Novartis, Amgen, Servier: Honoraria. Kantarjian: Amgen: Research Funding; Bristol-Meyers Squibb: Research Funding; ARIAD: Research Funding; Novartis: Research Funding; Pfizer: Research Funding; Delta-Fly Pharma: Research Funding. Recher: Celgene, Sunesis, Amgen, Novartis: Research Funding; Novartis, Celgene, Jazz, Sunesis, Amgen: Consultancy. Seymour: Celgene, Roche, Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie, Genentech: Research Funding. Dunbar: AbbVie: Employment, Equity Ownership. Xu: AbbVie: Employment, Equity Ownership. Mabry: AbbVie: Employment, Equity Ownership. Potluri: AbbVie: Employment, Equity Ownership. Letai: AbbVie, AstraZeneca, Novartis: Consultancy, Research Funding.